Annotation Detail
Information
- Associated Genes
- CD274
- Associated Variants
-
CD274 EXPRESSION
CD274 EXPRESSION - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1/PD-L1 monoclonal antibodies. Patients with PD-L1 positive tumors (PD-L1 tumor cell staining ≥1%), had a significantly higher ORR, compared to patients with PD-L1 negative tumors (OR: 2.44; 95% CIs: 1.61-3.68).
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1167
- Gene URL
- https://civic.genome.wustl.edu/links/genes/11335
- Variant URL
- https://civic.genome.wustl.edu/links/variants/276
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Atezolizumab,Nivolumab,Avelumab,Pembrolizumab
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26918451
Drugs
Drug Name | Sensitivity | Supported |
---|---|---|
Avelumab | Sensitivity | true |
Atezolizumab | Sensitivity | true |
Pembrolizumab | Sensitivity | true |
Nivolumab | Sensitivity | true |